

论著

疡愈涂剂对糖尿病大鼠创面 I、III 胶原合成及 MMPs、TIMP-1 表达的影响

盛巡¹, 李光善^{1,2}, 李萍^{1△}, 王芳¹, 梁代英¹, 刘欣¹, 黄启福²

1北京市中医研究所病理生理室, 北京 100010; 2北京中医药大学, 北京 100029

收稿日期 2005-1-18 修回日期 2005-3-24 网络版发布日期 2009-10-16 接受日期 2005-3-24

摘要 目的: 观察疡愈涂剂促进糖尿病迟缓愈合伤口的修复作用及其分子机制。方法: 实验分为对照组、模型组、疡愈涂剂高、中、低剂量组。除对照组外, 大鼠腹腔注射链脲佐菌素(STZ)55 mg/kg, 造成实验性高血糖。30 d后, 各组动物复合背部全厚皮切除直径为1.6 cm的伤口。分别观察疡愈涂剂对创面愈合时间、愈合率的影响; 天狼星红染色法以及免疫组化法观察 I、III型胶原含量及 I、III型胶原比值, 并观察金属蛋白酶-1、-13(MMP-1、-13)、金属蛋白酶抑制剂-1(TIMP-1)水平及MMP-1、-13 与TIMP-1比值。结果: 疡愈涂剂各剂量组创面愈合时间明显短于模型组(P<0.01), 愈合率明显高于模型组(P<0.01, P<0.05)。在伤口用药的第3、7、11 d, 高、中剂量组创面 I 型胶原含量以及 I、III型胶原比值显著高于模型组(P<0.01)。在伤口用药第3 d疡愈涂剂中剂量、第7、11 d各剂量组创面III型胶原显著高于模型组(P<0.01)。各剂量组在第7 d创面MMP-1、-13均高于模型组(P<0.01, P<0.05), 而MMP-1 在第11 d与模型组趋于一致且MMP-13明显低于模型组(P<0.01, P<0.05)。各剂量组在3、7、11 d创面TIMP-1均明显高于模型组(P<0.01, P<0.05), 在第11 d各剂量组MMP-1、TIMP-1比值明显低于模型组(P<0.01), 在第3、7 d高、中剂量组创面MMP-13、TIMP-1比值高于模型组(P<0.01), 而到第11 d高、中、低各剂量组均明显低于模型组(P<0.01); 第11 d高、中剂量组MMP-13、TIMP-1比值低于低剂量组(P<0.05)。结论: 疡愈涂剂可能通过调节影响胶原代谢的MMPs、TIMPs表达平衡, 促进胶原的合成和沉积, 从而加速创面的愈合。

关键词 [胶原 I 型](#); [胶原 III 型](#); [基质金属蛋白酶](#); [糖尿病](#); [金属蛋白酶1组织抑制剂](#)

分类号 [R363](#)

Effect of Yangyu Tuji on content of type I, III collagen and the expression of MMPs and TIMP-1 in wound caused by streptozotocin in rats

SHENG Xun¹, LI Guang-shan^{1,2}, LI Ping¹, WANG Fang¹, LIANG Dai-ying¹, LIU Xin¹, HUANG Qi-fu²

1Department of Pathophysiology, Beijing Institute of Traditional Chinese Medicine, Beijing 100010, China; 2Beijing University of Traditional Chinese Medicine, Beijing 100029, China

Abstract

AIM: To study the effects of Yangyu Tuji (YJTJ) on delayed healing wound of diabetic rats caused by streptozotocin (STZ). METHODS: SD male rats were randomly divided into control group (control), model group (model); and 3 different dose groups of YJTJ. 55 mg/kg STZ were given by intraperitoneal injection except for control group. After 30 days, a round skin of 1.6 cm diameter was excised on all dorsal back of rats. The healing time and healing rate were observed according to re-epithelization. The content of collagen I and III was observed by Picric acid-Sirius red staining, Matrix metalloproteinase-1, 13 (MMP-1, -13), tissue inhibitor of metalloproteinases-1 (TIMP-1) by immuno-histochemistry assay. All data were analyzed by IPP software. RESULTS: The healing time in each group treated with YJTJ was shorter than that in model group (P<0.01), and the healing rate was increased (P<0.01, P<0.05). Content of type I collagen, ratio of type I and III collagen of high and mid dose group were significantly higher than that in model group (P<0.01) at 3rd, 7th, 11th day. The expression of MMP-1, -13 of each groups were higher than that in model group at 7th day (P<0.01, P<0.05), and MMP-1 trend to equal with model group at 11th day. MMP-13 was significantly lower than that in model group at 11th day (P<0.01, P<0.05). TIMP-1 of each group of wound was higher than that in model group at 3rd, 7th, 11th day (P<0.01, P<0.05). The ratio of type I and III collagens in each group was lower than that in model group

扩展功能

本文信息

- ▶ [Supporting info](#)
- ▶ [PDF\(2937KB\)](#)
- ▶ [\[HTML全文\]\(0KB\)](#)
- ▶ [参考文献](#)

服务与反馈

- ▶ [把本文推荐给朋友](#)
- ▶ [加入我的书架](#)
- ▶ [加入引用管理器](#)
- ▶ [复制索引](#)
- ▶ [Email Alert](#)
- ▶ [文章反馈](#)
- ▶ [浏览反馈信息](#)

相关信息

- ▶ [本刊中 包含“胶原 I 型; 胶原 III 型; 基质金属蛋白酶; 糖尿病; 金属蛋白酶1组织抑制剂” 的相关文章](#)
- ▶ 本文作者相关文章

- [盛巡](#)
- [李光善](#)
- [李萍](#)
- [王芳](#)
- [梁代英](#)
- [刘欣](#)
- [黄启福](#)

at 11th day ($P<0.01$). Ratio of MMP-13 and TIMP-1 of high dose group and mid dose group were higher than that in model group at 3rd and 7th day ($P<0.01$). The ratio of each group was lower than that in model group at 11th day ($P<0.01$). Meanwhile, ratio of MMP-13 and TIMP-1 of high dose group and mid dose group were lower than that of lower dose group ($P<0.05$). CONCLUSION: It is possible that YYTJ accelerates wound healing by increasing collagen content of type I and III, especially type I, as well as improves collagen deposition by regulating the balance of MMP and TIMP.

Key words [Collagen type I](#) [Collagen type III](#) [Matrix metalloproteinases](#) [Diabetes mellitus](#) [Tissue inhibitor of metalloproteinases-1](#)

DOI: 1000-4718

通讯作者 李萍 liping411@yahoo.com.cn